Rhelion Life Sciences Corp.
TRUFF
$0.02
$0.008.42%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -30.62% | 65.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -30.62% | 65.70% | |||
| Cost of Revenue | -53.93% | 109.91% | |||
| Gross Profit | 28.48% | 8.04% | |||
| SG&A Expenses | -0.01% | 15.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.94% | 38.98% | |||
| Operating Income | 8.64% | -18.75% | |||
| Income Before Tax | -138.99% | -15.51% | |||
| Income Tax Expenses | -722.44% | 32.12% | |||
| Earnings from Continuing Operations | -127.19% | -17.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 1,977.16% | 38.10% | |||
| Net Income | -83.79% | -16.76% | |||
| EBIT | 8.64% | -18.75% | |||
| EBITDA | -75.94% | -21.01% | |||
| EPS Basic | -79.17% | -14.29% | |||
| Normalized Basic EPS | 100.00% | -20.00% | |||
| EPS Diluted | -412.50% | -14.29% | |||
| Normalized Diluted EPS | 100.00% | -20.00% | |||
| Average Basic Shares Outstanding | 1.69% | 1.30% | |||
| Average Diluted Shares Outstanding | 1.69% | 1.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||